Accurate 3D hand pose and pressure sensing is essential for immersive human-computer interaction, yet simultaneously achieving both in mobile scenarios remains a significant challenge. We present WristP2, a camera-based wrist-worn system that estimates 3D hand pose and per-vertex pressure from a single wide-FOV RGB frame in real time. A ViT (Vision Transformer) backbone with joint-aligned tokens predicts Hand–VQ–VAE codebook indices for mesh recovery, while an extrinsics-conditioned branch jointly estimates per-vertex pressure. On a self-collected dataset of 133,000 frames (20 subjects; 48 on-plane and 28 mid-air gestures), WristP2 attains MPJPE (Mean Per-Joint Position Error) of 2.9 mm, Contact \(\operatorname{IoU}\) of 0.712, \(\operatorname{Vol.IoU}\) of 0.618, and foreground pressure MAE of 10.4 g. Across three user studies, WristP2 delivers touchpad-level efficiency in mid-air pointing and robust multi-finger pressure control on an uninstrumented desktop. In a real-world large-display Whac-A-Mole task, WristP2 also enables higher success ratio and lower arm fatigue than head-mounted camera-based baselines. These results position WristP2 as an effective, mobile solution for versatile pose- and pressure-based interaction.

Cancer development and progression are driven by the accumulation of somatic genetic alterations, which occur in a specific temporal order. However, how the order of mutations impacts cancer phenotypes of solid tumors remains poorly understood. To address this, we developed a novel computational framework, IMOP-Cancer (Identifying Mutation Order Pairs in Cancer), to identify mutation gene pairs whose order influences cancer phenotypes. We applied IMOP-Cancer to The Cancer Genome Atlas-Lung Adenocarcinoma (TCGA-LUAD) cohort and identified 446 key mutation order pairs, with 34 pairs significantly associated with prognosis. Mutation order impacts cancer phenotypes, as demonstrated by CSMD3 and PTPRD (tumor proliferation) and TP53 and NAV3 (immune modulation), with effects validated in four independent datasets. We further presented the impact of mutation pairs on cancer phenotypes through case studies in the TCGA cohorts of bladder urothelial carcinoma (BLCA), and colon adenocarcinoma (COAD). We extended this analysis to 33 cancer cohorts from TCGA portal, identifying 106 034 critical mutation pairs across 17 cancers, with 3036 pairs co-occurring in multiple cancers. Shared mutation pairs across cancers also showed distinct effects on cancer phenotype. Our study highlights the importance of mutation order in cancer progression and diversity, offering new insights into the temporal dynamics of co-occurring mutations and paving the way for personalized treatment strategies and improved diagnosis.